Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TONI: T Cell Therapy for COVID-19 Prevention in HSCT Patients
NCT05141058Phase 1Recruiting
- Sponsor
- Children's National Research Institute
- Start
- Oct 2021
- Primary completion
- Nov 2028
- Modality
- Allogeneic CAR-T, Tumor-Infiltrating Lymphocytes (TILs), TCR-Engineered T Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of Partially HLA-matched SARS-CoVSTs in Coronavirus Disease 2019 (COVID-19) (3 arms), sponsored by Children's National Research Institute. Primary endpoints: Incidence of grade >=3 infusion-related Adverse Events at 45 days, Incidence of acute Graft Vs Host Disease grade >=3 at 45 days and 2 more. Started Oct 2021; status: recruiting.
02
Drugs
Partially HLA-matched SARS-CoVSTs
03
Conditions
Coronavirus Disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05141058.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05141058.